Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 40, Issue 10, 1997, Pages 1810-1816

  Belmont, H Michael ^a   Levartovsky, David ^a   Goel, Archana ^a   Amin, Ashok ^a   Giorno, Ralph ^b   Rediske, John ^c   Skovron, Mary Louise ^a   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE;

ARTICLE; CALORIMETRY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PRIORITY JOURNAL; SKIN BIOPSY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

ADULT; BIOPSY; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SKIN;

EID: 0030776828     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780401013     Document Type: Article

References (32)

1. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acelylcholine. Nature 288:373-376, 1980
2. Palmer RMJ, Ferrige G, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxant factor. Nature 327:524-526, 1987
3. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 84:9265-9269, 1987
4. Billiar TR: Nitric oxide: novel biology with clinical relevance. Ann Surg 221:339-349, 1995
5. Clancy RM, Abramson SB: Nitric oxide: a novel mediator of inflammation. Soc Exp Biol Med 210:93-101, 1995
6. G-Monomethyl-L-Arginine. J Exp Med 179:651-660, 1994
7. Gilkeson G, Cannon C, Goldman D, Petri M: Correlation of a serum measure of nitric oxide production with lupus disease activity measures (abstract). Arthritis Rheum 39 (suppl 9):S251, 1996
8. Belmont HM, Buyon J, Giorno R, Abramson S: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Shwartzman phenomenon revisited. Arthritis Rheum 37:376-383, 1994
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
11. Burger R, Zilow G, Bader A, Friedlein A, Naser W: The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential. J Immunol 141:553-558, 1988
12. 15N nitrate in biological fluids. Anal Biochem 126:131-138, 1982
13. Oates J, Alexander A, Pippen A, Gilkeson GS: Effect of modulation of nitric oxide production on murine SLE (abstract). Arthritis Rheum 39:S78, 1996
14. Gilkeson G, Seldin M, Mudgett J, Weinberg B: MRL-lpr mice lacking iNOS develop significant nephritis and arthritis (abstract). Arthritis Rheum 39 (suppl 9):S110, 1996
15. Lai KN, Leung JC, Lai KB, Lai FM, Wong KC: Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann Rheum Dis 55:57-62, 1996
16. Chan TM, Cheng IKP: A prospective study on anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 78:41-46, 1996
17. Quadros NP, Roberts-Thompson PJ, Gallus AS: Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumor necrosis factor alpha. Rheumatol Int 15:99-105, 1995
18. Habib A, Martinuzzo ME, Carreras LO, Levy-Toledano S, Maclouf J: Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. Thromb Haemost 74:770-777, 1995
19. Wagner AD, Björnsson J, Goronzy JJ, Weyand CM: Potential role of TGF-β1 and nitric oxide in human vasculitis (abstract). Arthritis Rheum 39 (suppl 9):S80, 1996
20. Radomski MW, Palmer RM, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2:1057-1058, 1987
21. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman A, Bove AA, Isaac L, Hrabie JA, Keefer LK: Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide: vasorelaxant effects. J Med Chem 34:3242-3247, 1991
22. Clancy RM, Leszczynska-Piziak J, Abramson SB: Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil Superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 90:1116-1121, 1992
23. Kubes PM, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88:4651-4655, 1991
24. Kubes P, Kurose I, Granger DN: NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in postischemic venules. Am J Physiol 267:H931-H937, 1994
25. Masini E, Pistelli A, Gambassi F, Di Bello MG, Mannaioni PF: The role of nitric oxide in anaphylactic reaction of isolated guinea pig hearts and mast cells. In, Nitric Oxide: Brain and Immune System. Edited by S Moncada, G Nishko. London, Portland Press, 1996
26. Murohara T, Parkinson SJ, Waldman SA, Lefer AM: Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets: role of protein kinase C. Arterioscler Thromb Vase Biol 15:2068-2075, 1995
27. Cooke JP, Tsao PS: Cytoprotective effects of nitric oxide. Circulation 88:2451-2455, 1993
28. Seekamp A, Mulligan MS, Till GO, Ward PA: Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury. Am J Pathol 142:1217-1226, 1993
29. Buckberg GD, Matheis G, Sherman MP, Haybron DM, Ignarro LJ: Myocardial reoxygenation injury after ischaemia is medicated by the L-arginine:nitric oxide pathway. In, The Biology of Nitric Oxide. Edited by S Moncada, MA Marletta, JB Hibbs Jr, EA Higgs. London, Portland Press, 1992
30. Lefer AM: Cytoprotective actions of nitric oxide donors in ischemia-reperfusion injury. In, The Biology of Nitric Oxide. Edited by S Moncada, MA Marletta, JB Hibbs Jr, EA Higgs. London, Portland Press, 1992
31. Zimmerman BJ, Granger DN: Reperfusion-induced leukocyte infiltration: role of elastase. Am J Physiol 259:H390-H394, 1990
32. Roissaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM: Inhaled oxide for the adult respiratory distress syndrome. N Engl J Med 328:399-405, 1993